ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision equipment becomes more valuable, but demand remains tied to export controls and capital spending cycles.
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Is Mirum Pharmaceuticals About to Soar in 2026? The future looks bright for this high-flying biotech stock.
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM) Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage powerhouse in the rare liver disease sector. As of early 2026, the company stands as a beacon of growth in the biotechnology landscape, recently surpassing annual revenue targets and achieving [...]
3 Top Growth Stocks to Buy in the First Half of 2026 Don't wait too long to make a decision on these three stocks.
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains.
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout.
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.
